Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A3 | P48764 | 12/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17350811 | 1.00 | SLC9A3 (0.61) | SLC9A3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL978917 | 1.00 | SLC9A3 (0.61) | SLC9A3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL982538 | 1.00 | SLC9A3 (0.61) | SLC9A3SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL6507416 | 0.99 | SLC9A3 (0.60) | SLC9A3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4028173 | 0.90 | SLC9A3 (0.61) | SLC9A3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13911315 | 0.88 | SLC6A2 (0.51) | SLC9A3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4030603 | 0.88 | SLC9A3 (0.59) | SLC9A3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16473674 | 0.88 | SLC9A3 (0.59) | SLC9A3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13285865 | 0.86 | SLC9A3 (0.58) | SLC9A3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6621393 | 0.86 | SLC9A3 (0.58) | SLC9A3SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613600-B1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THE USE OF THE SAME AS MEDICAMENTS, AND MEDICAMENT CONTAINING SUCH COMPOUNDS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2015-12-23 | — | — | EP | disclosed |
| US-7241775-B2 | Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| EP-1613600-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THE USE OF THE SAME AS MEDICAMENTS, AND MEDICAMENT CONTAINING SUCH COMPOUNDS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-01-11 | — | — | EP | disclosed |
| US-20050009863-A1 | Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-13 | — | — | US | disclosed |
| WO-2004085404-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, THE USE OF THE SAME AS MEDICAMENTS, AND MEDICAMENT CONTAINING SUCH COMPOUNDS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009863-A1 | Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines | CYP27A1, CYP11B2, CYP7A1 | SLC9A3 4035/4885SLC6A2 1036/4885SLC6A4 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.